Merck unveils $3 billion cost cutting plan

The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483

Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr

Revenue increased 11.4 per cent to Rs. 8,545 crore

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026

Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy

Capricor’s BLA for Deramiocel received Priority Review in March 2025

Veerhealth Care enters into contract manufacturing agreement

Commercial production is expected to begin soon